Publications de Bing Feng | EPFL Graph Search

A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response

JOHN WILEY & SONS LTD2025

Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy

© 2024 The AuthorsMany cancer immunotherapies rely on robust CD8+ T cells capable of eliminating cancer cells and establishing long-term tumor control. Recent insights into immunometabolism highlight the importance of nutrients and metabolites in T cell ac ...

2024

The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer

Mei-Wen Peng, Li Tang, Yugang Guo, Yang Zhao, Bing Feng, Lucia Bonati, Rongrong Li

Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1 ...

2024

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Yuqing Xie, Li Tang, Yugang Guo, Yang Zhao, Xiaomeng Hu, Bing Feng

The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in ...

Nature Portfolio2024

Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission

Li Tang, Bing Feng

Despite a high response rate in chimeric antigen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL)1–3, approximately 50% of patients relapse within the first year4–6, representing an urgent question to address in the next stage of cellula ...

2024

A redox-responsive prodrug for tumor-targeted glutamine restriction

Xile Hu, Daniel Ortiz Trujillo, Li Tang, Céline Jasmin Prange, Bing Feng

Modulating the metabolism of cancer cells, immune cells, or both is a promising strategy to potentiate cancer immunotherapy in the nutrient-competitive tumor microenvironment. Glutamine has emerged as an ideal target as cancer cells highly rely on glutamin ...

Elsevier2024

Highly effective adoptive t cell therapy

Li Tang, Yugang Guo, Bing Feng

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions ...

2023

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Li Tang, Bing Feng

Amer Soc Hematology2023

A bispecific nanomodulator to potentiate photothermal cancer immunotherapy

Bing Feng

Photothermal therapy (PTT) has shown great potential in cancer treatment for inducing photothermal ablation and eliciting immune responses. However, PTT-triggered antitumor immunity is severely hampered by the dynamic amplification of programmed cell death ...

2022

Editorial: Metabolic Intervention Based on Functional Biomaterial Strategy to Potentiate Cancer Immunotherapy, Volume I

Bing Feng

FRONTIERS MEDIA SA2022

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

Li Tang, Bing Feng, Thomas Gruber

Background The use of intralesional Mycobacterium bovis BCG (intralesional live BCG) for the treatment of metastatic melanoma resulted in regression of directly injected, and occasionally of distal lesions. However, intralesional-BCG is less effective in p ...

BMJ PUBLISHING GROUP2022

Delivery of STING agonists for adjuvanting subunit vaccines

Li Tang, Bing Feng, Simon Bart M. Van Herck

Adjuvant is an essential component in subunit vaccines. Many agonists of pathogen recognition receptors have been developed as potent adjuvants to optimize the immunogenicity and efficacy of vaccines. Recently discovered cyclic GMP-AMP synthase-stimulator ...

ELSEVIER2021

Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity

Li Tang, Yugang Guo, Yang Zhao, Min Gao, Bing Feng

Tang and colleagues show that a half-life-extended IL-10-Fc fusion protein acts directly on terminally exhausted PD1(+)TIM-3(+)CD8(+) T cells to enhance their proliferation and effector function by reprogramming the cellular metabolism to oxidative phospho ...

2021